CTI Biopharma Corp CTIC:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/05/21 EST
2.97quote price arrow up+0.01 (+0.34%)
Volume
831,730
52 week range
0.62 - 4.03

...

Loading . . .

KEY STATS

  • Open2.98
  • Day High3.05
  • Day Low2.63
  • Prev Close2.97
  • 52 Week High4.03
  • 52 Week High Date11/23/20
  • 52 Week Low0.62
  • 52 Week Low Date03/16/20
  • Market Cap224.15M
  • Shares Out75.47M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta0.87
  • 1 Year % Change201.22

RATIOS/PROFITABILITY

  • EPS (TTM)-0.68
  • P/E (TTM)-4.34
  • Fwd P/E (NTM)-4.26
  • EBITDA (MRQ)-37.714M
  • ROE (MRQ)-115.87%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)80.74%
  • Net Margin (MRQ)-1,940.54%
  • Debt To Equity (MRQ)12.08%

EVENTS

  • Earnings Date03/11/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest CTI Biopharma Corp News

There is no recent news for this security.

Latest CTIC News From Our Partners

QUOTE FINDER

Profile

MORE
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult...
Address
3101 Western Ave Ste 800
Seattle, WA
98121-3017
United States